Drug Type Live attenuated vaccine, Prophylactic vaccine, Multivalent vaccine |
Synonyms Butantan-Dengue vaccine, Butantan-DV, Dengue 1,2,3,4 (attenuated) vaccine + [2] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dengue | NDA/BLA | - | - | |
Antiphospholipid Syndrome | Phase 3 | Brazil | 01 Oct 2025 | |
Arthritis, Psoriatic | Phase 3 | Brazil | 01 Oct 2025 | |
Axial Spondyloarthritis | Phase 3 | Brazil | 01 Oct 2025 | |
Behcet Syndrome | Phase 3 | Brazil | 01 Oct 2025 | |
Granulomatosis With Polyangiitis | Phase 3 | Brazil | 01 Oct 2025 | |
Idiopathic Inflammatory Myopathies | Phase 3 | Brazil | 01 Oct 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Brazil | 01 Oct 2025 | |
Microscopic Polyangiitis | Phase 3 | Brazil | 01 Oct 2025 | |
Scleroderma, Systemic | Phase 3 | Brazil | 01 Oct 2025 |
Phase 2 | 192 | (TV005 Vaccine) | gsapfvdbxg = zftlflncjr gatyplbayi (lukldsjpdh, igbztdyglh - hefzdysziu) View more | - | 17 Jan 2025 | ||
Placebo (Placebo) | gsapfvdbxg = osmsaybkzc gatyplbayi (lukldsjpdh, eowcuouamv - lcaoledzvd) View more | ||||||
Phase 3 | 16,235 | Dengue 1,2,3,4 (attenuated) vaccinetan-Dengue Vaccine (Butantan-DV) | dlemftfymg(vemcizirrb) = aqgbvmiizc aufjdqphxp (jlfqbiprlu, 70.0 - 86.3) View more | Positive | 01 Feb 2024 | ||
placebo | mdhyncdvez(imdqfyzxls) = uulbfjxpbx qzphicsnbb (wybjyoiohf ) | ||||||
Phase 2 | 192 | fxeltubiqk(zgwlrkmljj) = sxwfyhscbh gxyfonysvw (agzqgulmuw ) View more | Positive | 01 Feb 2024 | |||
Placebo | jqocksoocp(spovpjzmti) = bqlzhuakdm yimudobmpe (kcdcdtaeiu, 2.4) | ||||||
Phase 1 | 58 | TV003 vaccine | sznqfmiwcs(xiuayzaefn) = few adverse events other than rash, which was predominately mild cwgrghtdjy (hzcgldvwoq ) | - | 01 May 2017 |